Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids
- 14 July 2021
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 42 (8) , 1403-1409
Abstract
We compared the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) with atovaquone for pneumocystis pneumonia (PCP) in patients with connective tissue diseases (CTDs) receiving high-dose glucocorticoids. Patients with CTDs aged ≥ 18 years who were treated with a prolonged course (≥ 4 weeks) of glucocorticoids (≥ 20 mg/day prednisone) in a Japanese tertiary center between 2013 and 2017 were included. The patients were categorized into two groups: TMP-SMX and atovaquone group. Adjusted cumulative incidence of PCP was compared between the two groups after propensity score weighting for differences in confounding factors. A total of 480 patients with a prolonged high-dose glucocorticoid treatment were identified. Out of 383 patients with TMP-SMX prophylaxis, 102 (26.8%) patients experienced adverse events leading to discontinuation within 4 weeks of initiation, while no patient in the atovaquone discontinued the therapy. Two hundred eighty-one patients received TMP-SMX, while 107 received atovaquone for PCP prophylaxis. During a total of 397.0 person-years, 7 PCP cases (2 in the TMP-SMX, 5 in the atovaquone) occurred with a mortality rate of 54.5%. After adjusting for differences in baseline characteristics, the adjusted cumulative incidence of PCP was similar between the two group (HR 0.97, 95% CI 0.19-5.09, p = 0.97). Prophylactic effects for PCP in CTDs patients receiving prolonged high-dose glucocorticoids were similar between TMP-SMX and atovaquone. Atovaquone was well-tolerated with no side effects.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- A dose-escalation regimen of trimethoprim–sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseasesModern Rheumatology, 2012
- Atovaquone versus trimethoprim–sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantationClinical Transplantation, 2012
- Blood (1->3)- -D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii PneumoniaClinical Infectious Diseases, 2011
- An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care PatientsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pharmacokinetics and drug metabolism in the elderlyDrug Metabolism Reviews, 2009
- Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosusRheumatology International, 2008
- Failure of Low‐Dose Atovaquone Prophylaxis againstPneumocystis jiroveciInfection in Transplant RecipientsClinical Infectious Diseases, 2004
- A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1999
- Atovaquone Suspension Compared with Aerosolized Pentamidine for Prevention ofPneumocystis cariniiPneumonia in Human Immunodeficiency Virus–Infected Subjects Intolerant of Trimethoprim or SulfonamidesThe Journal of Infectious Diseases, 1999
- Trimethoprim-SulfamethoxazoleMayo Clinic Proceedings, 1999